INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

1. Pomerantz LLP investigates potential securities fraud by Ultragenyx executives. 2. Ultragenyx's stock fell over 25% after recent trial analysis announcement. 3. The Orbit study's final analysis is expected by year-end 2025. 4. Investigations could lead to class action lawsuits against Ultragenyx. 5. Past actions of Pomerantz may indicate significant implications for investors.

Legal

85

5m saved

Insight

Article

FAQ

Why Very Bearish?

The investigation into securities fraud has previously led to severe stock drops. Historical examples show class actions often depress share prices significantly during legal proceedings.

How important is it?

The ongoing investigations and lawsuit risks are highly relevant, likely affecting RARE's market sentiment and trading activity.

Why Short Term?

The current investigation and potential lawsuits create immediate uncertainty affecting stock prices. Similar incidents have historically caused short-term volatility.

Related Companies

MREO VRTX AMGN

Pomerantz LLP Investigates Claims on Behalf of Ultragenyx Pharmaceutical Inc. Investors

NEW YORK, July 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Ultragenyx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

Click here for information about joining the class action

On July 9, 2025, Ultragenyx and its development partner Mereo BioPharma Group plc issued a press release "announc[ing] that the randomized, placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward a final analysis[.] Following a Data Monitoring Committee meeting, the two companies advised that the final analysis would occur "around the end of the year."

On this news, Ultragenyx's stock price fell $10.41 per share, or 25.11%, to close at $31.04 per share on July 10, 2025.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, London, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT: Danielle Peyton, Pomerantz LLP [email protected] 646-581-9980 ext. 7980

SOURCE Pomerantz LLP